Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node RadiationMonika L. Metzger, Matthew J. Krasin, Susan M. Hiniker et al.|Journal of Clinical Oncology|2021Cited by 59
Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: a single institutional experienceAimee C. Talleur, Brandon M. Triplett, Jamie E. Flerlage et al.|Bone Marrow Transplantation|2020Cited by 7
Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08Jamie E. Flerlage, M Link, Angela M. Feraco et al.|Blood|2026Cited by 2
Metabolic-only response assessment for omission of residual node radiation therapy (RNRT) for patients with classical Hodgkin lymphoma (cHL) and impact on event free (EFS) and overall survival (OS): A report from the Pediatric Hodgkin Consortium’s phase 2 study cHOD17 (NCT03755804).Jamie E. Flerlage, Angela M. Feraco, Yiwang Zhou et al.|Journal of Clinical Oncology|2025Cited by 0
32 | METABOLIC‐ONLY RESPONSE ASSESSMENT ALLOWS RADIATION OMISSION FOR MAJORITY WITH CLASSICAL HODGKIN LYMPHOMA AND MAINTAINS EXCELLENT OUTCOMES: A PHC PHASE 2 STUDY cHOD17Jamie E. Flerlage, Matthias J. Ehrhardt, Angela M. Feraco et al.|Hematological Oncology|2025Cited by 0